IdeaCrew provides a state-based exchange technology solution that aims to make it easier for people to sign up for and retain healthcare coverage. The company works with states that are not using the federal marketplace platform and helps them provide a cost-effective, streamlined exchange to their residents.
While the White House and doctors at Walter Reed have sought to reassure the public that Trump's condition is improving, he has received numerous drugs for Covid-19, including the steroid dexamethasone, which is typically administered only to those who are critically ill.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
In a wide-ranging interview for BIO's virtual annual meeting with the trade and lobbying group's president, NIAID Director Anthony Fauci also said "good-faith" discussions are important to avoiding excessive pricing and ensuring affordability and access.
The study, published in The Lancet, found a possible association between hydroxychloroquine and chloroquine and heart arrhythmias and death. Meanwhile, SingleCare saw a as much as a 22% increase in scripts filled for hydroxychloroquine following Trump's remarks last week.
Rick Bright's attorneys said in an emailed statement Friday that the Office of the Special Counsel would request a 45-day stay on Bright's removal as director of BARDA. Bright was removed over his objections to broad use of two malaria drugs in Covid-19.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In a joint statement, FDA Commissioner Stephen Hahn and FTC Chairman Joseph Simons said they would look into anticompetitive practices like preventing biosimilar makers from obtaining product samples and misleading communications about biosimilars' safety and efficacy.
BIO's first annual report on diversity in the workplace found room for improvement, as biotech workforces - especially at the executive level - were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.
Under the decision, Medicare patients with inherited cancer mutations such as BRCA will receive coverage for NGS testing. Drugs that treat BRCA-mutated breast and ovarian cancers include AstraZeneca's Lynparza and Pfizer's Talzenna.
The Medicare coverage decision, issued Wednesday evening after a nearly three-month delay, removes several requirements that some had feared would limit access to the cell therapies, while also allowing for some off-label use.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Washington Post and other outlets reported that the administration has withdrawn a proposal to end rebates between pharmacy benefit managers and drugmakers.
The executive order is focused on increasing the supply of kidneys available for transplants, improving prevention and treatment of chronic kidney disease and pushing the majority of dialysis patients to get their treatment through less-costly and more convenient home care.
U.S. District Judge Amit Mehta in Washington, D.C. ruled in favor of pharma companies challenging the rule in court because of what he said was a lack of statutory authority from the HHS to govern drug marketing.
In a letter addressed to Gottlieb, Warren implored him to resign from board of the Big Pharma company, writing "this kind of revolving door influence-peddling smacks of corruption."
A order released Monday directs the Department of Health and Human Services to start the rulemaking process to require that providers divulge the prices that patients and insurers pay in a readable format.